Charles River Laboratories International, Inc. $CRL Shares Sold by Alyeska Investment Group L.P.

Key Points

• Alyeska Investment Group cut its Charles River Laboratories stake by 57.9% in the second quarter, selling 323,633 shares and retaining 235,000 shares worth about $53.3 million. Institutional investors collectively own 98.91% of CRL.
• Charles River’s latest quarterly results beat expectations, with EPS of $3.02 versus the $2.77 consensus and revenue of approximately $1 billion, although revenue fell 2.7% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $255.65.
• Insider selling continued, including Director James C. Foster’s sale of 33,561 shares for roughly $10.1 million under a pre-arranged Rule 10b5-1 plan. Longer-term earnings forecasts improved, but several near-term estimates were reduced, reflecting mixed growth expectations.

Alyeska Investment Group L.P. decreased its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 57.9% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 235,000 shares of the medical research company's stock after selling 323,633 shares during the period. Alyeska Investment Group L.P. owned about 0.49% of Charles River Laboratories International worth $53,296,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Avidity Partners Management LP bought a new stake in shares of Charles River Laboratories International in the 1st quarter valued at approximately $1,670,000. Handelsbanken Fonder AB lifted its stake in Charles River Laboratories International by 36.9% during the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company's stock worth $4,378,000 after purchasing an additional 5,200 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Charles River Laboratories International by 21.8% in the first quarter. California State Teachers Retirement System now owns 56,972 shares of the medical research company's stock worth $9,828,000 after purchasing an additional 10,207 shares during the period. Maverick Capital Ltd. acquired a new position in Charles River Laboratories International in the first quarter worth $1,411,000. Finally, WINTON GROUP Ltd bought a new stake in Charles River Laboratories International during the fourth quarter valued at $9,209,000. 98.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director James C. Foster sold 33,561 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at $9,478,800. This represents a 51.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the business's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares in the company, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 165,990 shares of company stock valued at $42,606,388. 1.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CRL shares. TD Cowen increased their target price on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a report on Monday, August 10th. CLSA downgraded shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price objective for the company. in a research report on Monday, July 20th. Evercore reiterated an "outperform" rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Finally, Barclays reissued an "overweight" rating and issued a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $255.65.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Long-term earnings outlook improved. Zacks Research raised its EPS forecasts for fiscal 2026 to $11.15 from $10.91, fiscal 2027 to $12.49 from $12.11, and fiscal 2028 to $13.82 from $13.01. Estimates also increased for several future quarters, signaling greater confidence in CRL’s longer-term growth prospects.
• Positive Sentiment: Enterovirus vaccine collaboration could generate future demand. Medigen has partnered with Charles River in an effort to bring an enterovirus vaccine to global markets. The initiative could create additional opportunities for CRL’s contract research, testing, and development services. Medigen links up with Charles River in push to take enterovirus vaccine global
• Neutral Sentiment: Recent operating results provide a mixed backdrop. CRL’s latest quarterly EPS of $3.02 exceeded the $2.77 consensus estimate, and revenue reached approximately $1 billion. However, revenue declined 2.7% year over year, while the company’s full-year 2026 EPS guidance remains $11.15-$11.45, close to the analyst consensus.
• Negative Sentiment: Director sold a sizable stake. James C. Foster sold 33,561 shares for about $10.1 million at an average price of $300, reducing his direct ownership by 51.5%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which makes it a less definitive bearish signal, but the size of the sale may pressure investor sentiment. SEC insider transaction filing
• Negative Sentiment: Some near-term estimates were lowered. Zacks trimmed its EPS forecasts for the third and fourth quarters of 2026, the first quarter of 2027, and the fourth quarter of 2027. These modest cuts suggest near-term uncertainty despite the stronger full-year and longer-term projections.

Charles River Laboratories International Price Performance

NYSE CRL opened at $291.80 on Monday. The company has a 50-day moving average price of $246.06 and a two-hundred day moving average price of $197.39. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $303.30. The stock has a market cap of $13.93 billion, a price-to-earnings ratio of -60.16, a price-to-earnings-growth ratio of 3.03 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source